Rezera

Privately held: no public share price · United Kingdom

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
NLRP3 inflammasomeSmall molecule
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026Topline resultRuvonoflastRESOLVE-2 Phase 2a topline: ruvonoflast with semaglutide
US · Rezera · Source ↗
9 September 2026Topline resultNT-0796RESOLVE-1 Phase 2 meets primary hsCRP endpoint
Rezera Inc. (formerly NodThera) · Source ↗

Financial reports

No financial reports recorded.